California-Based Mithrl Raises $20M in Series A Funding

The round also saw participation from Headline, AGI House, and pharma executives.

The company plans to use the funding to roll out its second-generation platform, Mithrl-1, which combines its biomedical world model with an agentic system for model routing, token optimization and context orchestration.

What is Mithrl?

Mithrl provides AI infrastructure for biopharma companies developing medicines and conducting biomedical research.

Its platform combines a proprietary biomedical world model with AI agents that work with peer-reviewed scientific literature, public and partnered datasets, and a client's proprietary data.

Read More:Colorado-Based Polaris Electro-Optics Raises $50M in New Funding

Mithrl-1 is deployed directly in each client's environment and can work with the AI models already used by the organization. This allows teams to build and manage their own biomedical AI agents without being locked into a single model or vendor roadmap.

The system also provides information about the evidence behind each hypothesis, along with a confidence score, helping research teams review how an answer was produced.

How Much Funding Has Mithrl Raised?

Mithrl has raised $20 million in its latest Series A funding round.

The source did not provide details of earlier funding rounds or Mithrl's total funding to date.

Who Invested in Mithrl’s Series A Round?

Obvious Ventures led the Series A funding round.

Other participants include:

• Headline
• AGI House
• Pharma executives

Why the Funding Matters

Mithrl will use the new funding to roll out Mithrl-1, its second-generation AI infrastructure platform.

The platform combines Mithrl's biomedical world model with an agentic harness designed for model routing, token optimization and context orchestration.

Mithrl says its platform has contributed to more than half a dozen customer-owned patent filings. In a recent benchmark, the platform also used 45% fewer tokens than standard workflows using the same frontier models.

Who founded Mithrl?

Mithrl was founded in 2023 by Vivek Adarsh and Shara Balakrishnan.

The company is headquartered in San Francisco, California.

Market and Business Growth

Mithrl is already deployed across top-10 pharmaceutical companies, clinical-stage biotechs and genomics platform partners.

The company says its biomedical world model delivers 16 times more primary evidence per answer than frontier models alone. It also scored 0.96 for scientific correctness in expert-rated biomedical benchmarks, compared with 0.60 without Mithrl's proprietary knowledge system.

Mithrl's platform has contributed to more than half a dozen customer-owned patent filings.

What Happens Next?

Mithrl will roll out Mithrl-1 across its biopharma customers.  

The company plans to continue deploying its AI infrastructure directly within client environments, allowing research teams to build and operate their own biomedical AI agents using validated scientific knowledge and their proprietary data.

“Every player in this category is racing to generate more raw hypotheses, faster. But the industry is cracking under the weight of hypotheses it can't triage or validate,” says Vivek Adarsh, Co-Founder and CEO of Mithrl. “We built Mithrl to answer a different question: which of these will actually hold up in downstream experiments, and ultimately in patients? The platform doesn't guess.

“The AI-for-biology stack is getting crowded at the app layer, but the durable advantage lives in the middle, the proprietary data, world models, and custom infrastructure each biopharma team needs,” says Rohan Ganesh, Partner at Obvious Ventures.

Read More:California-Based Factory Raises $200M in Funding